Wall Street analysts expect Chromadex Corp (NASDAQ:CDXC) to announce sales of $10.80 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Chromadex’s earnings. The lowest sales estimate is $10.61 million and the highest is $11.00 million. Chromadex posted sales of $7.80 million in the same quarter last year, which suggests a positive year-over-year growth rate of 38.5%. The business is scheduled to issue its next earnings results on Thursday, August 8th.
On average, analysts expect that Chromadex will report full-year sales of $47.13 million for the current year, with estimates ranging from $45.22 million to $49.05 million. For the next year, analysts anticipate that the company will post sales of $78.71 million, with estimates ranging from $67.42 million to $90.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for Chromadex.
Chromadex (NASDAQ:CDXC) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.04). Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%. The company had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.80 million.
CDXC has been the subject of several recent analyst reports. B. Riley reiterated a “buy” rating on shares of Chromadex in a research note on Friday, March 8th. Zacks Investment Research downgraded shares of Chromadex from a “buy” rating to a “hold” rating in a report on Monday, March 11th. ValuEngine upgraded shares of Chromadex from a “hold” rating to a “buy” rating in a report on Monday, March 25th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Chromadex in a report on Thursday, April 25th. Finally, BidaskClub upgraded shares of Chromadex from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. Chromadex presently has an average rating of “Hold” and an average price target of $6.00.
Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA purchased a new position in Chromadex during the 1st quarter valued at about $34,000. Resources Investment Advisors Inc. increased its holdings in Chromadex by 125.0% during the 4th quarter. Resources Investment Advisors Inc. now owns 9,000 shares of the company’s stock valued at $31,000 after acquiring an additional 5,000 shares in the last quarter. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in Chromadex during the 1st quarter valued at about $42,000. Spark Investment Management LLC purchased a new position in Chromadex during the 1st quarter valued at about $78,000. Finally, Rhumbline Advisers increased its holdings in Chromadex by 53.3% during the 4th quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock valued at $166,000 after acquiring an additional 16,863 shares in the last quarter. Hedge funds and other institutional investors own 18.11% of the company’s stock.
Shares of NASDAQ CDXC traded up $0.44 during midday trading on Thursday, hitting $4.63. The company had a trading volume of 957,815 shares, compared to its average volume of 193,883. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.24 and a quick ratio of 1.68. Chromadex has a twelve month low of $2.79 and a twelve month high of $5.00. The firm has a 50-day simple moving average of $4.26. The firm has a market cap of $257.07 million, a price-to-earnings ratio of -7.59 and a beta of 1.16.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Recommended Story: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.